SCHEMBL19200432

SCHEMBL19200432

CC1CCCCCCCN1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
CHRM2 P08172 4/20 0.38
CHRM4 P08173 3/20 0.38
CHRM5 P08912 3/20 0.38
CHRM1 P11229 3/20 0.38
CHRM3 P20309 3/20 0.38
CYP2D6 P10635 2/20 0.38
ALDH1A1 P00352 2/20 0.38
SLC6A2 P23975 2/20 0.38
SLC6A4 P31645 2/20 0.38
SLC6A3 Q01959 2/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
CYP1A2 P05177 1/20 0.38
KMT2A Q03164 1/20 0.38
MLNR O43193 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16364352 1.00 TSHR (0.45) TSHRTDP1CYP2C9CYP2C19CHRM2
SCHEMBL2101753 1.00
SCHEMBL16572707 1.00 TSHR (0.45) TSHRTDP1CYP2C9CYP2C19CHRM2
SCHEMBL14117903 1.00 TSHR (0.45) TSHRTDP1CYP2C9CYP2C19CHRM2
SCHEMBL17573237 1.00 TSHR (0.45) TSHRTDP1CYP2C9CYP2C19CHRM2
SCHEMBL2099026 1.00
SCHEMBL446418 1.00
SCHEMBL15929564 1.00 TSHR (0.45) TSHRTDP1CYP2C9CYP2C19CHRM2
SCHEMBL20636071 1.00
SCHEMBL28416123 1.00 TSHR (0.45) TSHRTDP1CYP2C9CYP2C19CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4108661-A1 ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC DEVICE Idemitsu Kosan Co.,Ltd. (JP) 2022-12-28 EP disclosed
US-20220160995-A1 METHODS AND DEVICES FOR MODULATION OF INTEGRATED NEURAL NETWORKS TO INFLUENCE COMPOSITE SENSORY PROCESSES IST, LLC 2022-05-26 US disclosed
US-10793304-B2 High-flow, low-velocity gas flushing system for reducing and monitoring oxygen content in packaged produce containers DOLE FRESH VEGETABLES, INC. (US) 2020-10-06 US disclosed
WO-2019243533-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2019-12-26 WO disclosed
US-20190151483-A1 METHODS OF MAKING 18F-LABELED PRECURSORS AND PEPTIDES, LABELED C-MET BINDING PEPTIDES, AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2019-05-23 US disclosed
US-20190071441-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2019-03-07 US disclosed
US-10174025-B2 Pyrazole derivative manufacturing method MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2019-01-08 US disclosed
WO-2018071622-A1 3-SULFONYL-5-AMINOPYRIDINE-2,4-DIOL APJ AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-04-19 WO disclosed
US-20180099964-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2018-04-12 US disclosed
WO-2018022603-A1 METHODS OF MAKING 18F-LABELED PRECURSORS AND PEPTIDES, LABELED C-MET BINDING PEPTIDES, AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2018-02-01 WO disclosed
US-9879009-B2 Pyrazole derivative manufacturing method MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2018-01-30 US disclosed
US-9777000-B2 Pyrazole derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2017-10-03 US disclosed
US-9775845-B2 Carbazole-containing sulfonamides as cryptochrome modulators RESET THERAPEUTICS, INC. (US) 2017-10-03 US disclosed
US-20170217958-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2017-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170217958-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD CYP3A7, CYP2C19, CYP3A5 TSHR 1311/4885TDP1 3034/4885CYP2C9 9/4885
US-10174025-B2 Pyrazole derivative manufacturing method CYP3A5, CYP3A7, CYP3A4 TSHR 1457/4885TDP1 2251/4885CYP2C9 7/4885
US-20180099964-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD CYP3A5, CYP3A7, CYP3A4 TSHR 1457/4885TDP1 2251/4885CYP2C9 7/4885
US-20190071441-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD CYP3A5, CYP3A7, CYP3A4 TSHR 1457/4885TDP1 2251/4885CYP2C9 7/4885
US-20190151483-A1 METHODS OF MAKING 18F-LABELED PRECURSORS AND PEPTIDES, LABELED C-MET BINDING PEPTIDES, AND METHODS OF USE THEREOF MET, MYCBP, METTL14 TSHR 333/4885TDP1 4247/4885CYP2C9 4214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.